MassBio Annual Meeting 2014

Thursday, April 3 – Friday, April 4 2014


MassBio Annual Meeting
April 3-4, 2014
Royal Sonesta Hotel, 40 Edwin Land Blvd, Cambridge, MA

Thursday, April 3
Friday, April 4

Thursday, April 3              


8:00 am - 9:00 am             Breakfast and Poster Presentation                                       

9:00 am - 9:30 am             Welcome Remarks, Overview of Meeting, and MassBio Board Elections                         

9:30 am - 10:15 am          Opening Keynote: Brad Margus, CEO of Genome Bridge                     

10:15 am - 10:30 am        Coffee Break                             

10:30 am - 11:30 am        Breakout Sessions

Business Track: The Image Problem of the BioPharma Industry 


  • Lisa Adler, Vice President, Corporate Communications, Millennium: The Takeda Oncology Company
  • Maria Cantor, Senior Vice President, Corporate Affairs and Human Resources, ARIAD
  • Karen Carolonza, Principal, Strategy, Green Room Communications
  • Lori Gorski, Director, Corporate Communications, Genzyme


  • Luke Timmerman, Biotechnology Journalist

Science Track:    Clinical Trial Trends           


  • Neil Bodick, Chief Medical Officer & Co-Founder, Flexion Therapeutics
  • Marc Foster, Co-Founder & COO, Transparency Life Sciences
  • Amy O’Donnell, Executive Medical Director, Medical and Scientific Affairs, inVentiv Health Clinical
  • Richard Peters, Vice President & Division Medical Officer, Sanofi Oncology


  • Mark de Rosch, Vice President of Regulatory Drugs/Biologics and Head of US Operations, Voisin Consulting Life Sciences                

11:45 am – 1:30 pm   Awards Luncheon

11:45 am – 12:00 pm       Awards Luncheon: Lunch is served

12:00 pm – 12:20 pm       Leading Impact Award

12:20 pm – 12:45pm        2013 Joshua Boger Innovative School of the Year Award

12:45 pm – 1:30 pm         Henri A. Termeer Innovative Leadership Award                                         

1:30 pm - 2:15 pm            Conference Wide Panel:  Impact 2020 Overview            


  • Glenn Batchelder, Founder & Board Member, Civitas Therapeutics
  • Katrine Bosley, Entrepreneur-in-residence, Broad Institute
  • Skip Irving, Partner and Managing Director, Health Advances
  • Terry McGuire, Co-Founder & General Partner, Polaris Partners


  • Rob Weisman, Healthcare Business Writer, The Boston Globe


2:15 pm - 3:15 pm            Breakout Sessions          

Business Track: Beg, Borrow & Crowdsource? Innovative Ways to Fund Your Early Stage Company         


  • Alex Fair, Co-Founder and CEO, MedStartR
  • Barbara Fox, CEO & Founder, Avaxia Biologlics, Inc.
  • Dan Lilly, Government Sales Advisor, Massachusetts Small Business Development Center
  • Andrew Lo, Professor and Director, MIT Laboratory for Financial Engineering
  • Brock Reeve, Portfolio Manager, Poliwogg


  • Margaret Anderson, Executive Director, FasterCures

Science Track:    Challenges to Managing Big Data     


  • Bill Crown, Chief Scientific Officer, Optum Labs
  • Anil Jain, Chief Medical Information Officer, Explorys, Inc.
  • Iya Khalil, Executive Vice President and Co-Founder, GNS Healthcare
  • Peter Neumann, Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center


  • Jeff Elton, Managing Director of Life Sciences, Accenture


3:15 pm - 3:30 pm            Afternoon Break             

3:30 pm - 4:30 pm            Breakout Sessions

Business Track: Winning Strategies in Business and Corporate Development: What are They and How Can We Learn From Them? 


  • Tariq Kassum, Vice President, Business Development and Strategy, Millennium: The Takeda Oncology Company
  • Tomas Landh, Director, Strategy and Innovation Sourcing, Diabetes, Novo Nordisk
  • Jason Rhodes, President & CFO, Epizyme


  • Jay Mohr, Managing Director and Co-Founder, Locust Walk Partners

Science Track:    The Second Coming of Molecular Therapies       


  • Philip Astley-Sparke, President US, uniQure
  • Stéphane Bancel, President and Founding Chief Executive Officer, Moderna
  • Kevin Bitterman, Interim CEO, Editas Medicine and Principal, Polaris Partners
  • Nick Leschly, chief bluebird, bluebird bio


  • Fred Ledley, Professor and Director at Center for Integration of Science and Industry, Bentley University


4:30 - 6:30 pm    Reception          


Friday, April 4                   


8:00am - 8:30 am              Breakfast                                        

8:30 - 9:30 am    Breakout Sessions          

Business Track: Addressing Opportunity Cost When We Focus on Rare Disease


  • Cristina Csimma, CEO, Cydan Development
  • Laurence Reid, Senior Vice President and Chief Business Officer, Alnylam
  • Rajeev Shah, Partner, RA Capital Management
  • Andre Turenne, Vice President & Head of Strategy and Business Development, Genzyme


  • Barry Werth, Author

Science Track: Mobile Technology and 3D Printing: Technologies Gaining Traction in Biotech and Pharma            


  • Scott DeFelice, President, Oxford Performance Materials
  • David Kolesky, PhD Candidate, Lewis Research Group, Harvard University
  • Jacques Kpodonu, Cardiac Surgeon, Beth Israel Deaconess Medical Center
  • Ravi Kuppuraj, CTO & Co-Founder, InfoBionic


  • Navjot Singh, Director, McKinsey & Company

9:45 am - 10:45 am           Breakout Sessions

Business Track: Converging Relationships Among Biotech, Pharma, Investors, and Academia  


  • Jane Amara, Director (interim),Technology & Innovation Development Office, Boston Children’s Hospital
  • Kathy Bowdish, Vice President Global R&D and Head of Sunrise
  • Judith Dunn, Global Head of pRED Clinical Development, Hoffmann-La Roche
  • Ben Thorner, Associate Vice President, Head of Business Development and Licensing, Boston Innovation Hub, Merck Research Laboratories
  • James Tobin, Vice President, Cardiovascular and Scientific Innovation, Johnson & Johnson


  • Jonathan Gertler, Managing Partner and CEO, Back Bay Life Sciences Advisors

Science Track:    New Approaches to Treatments for Neurological Disease    


  • Zaven Kaprielian, Director of Neuroscience Research, Amgen
  • Jeffrey Nye, Vice President Neuroscience Innovation and Scientific Partnership Strategy, Janssen Research and Development, LLC, Johnson and Johnson Innovation
  • Mark Perrin, CEO, InVivo Therapeutics


  • Dennis Selkoe, Co-Director, Center for Neurologic Diseases, Brigham and Women's Hospital at the Harvard Institutes of Medicine  


10:45 am - 11:00 am        Coffee Break    

11:00 am - 12:00 pm        Conference Wide Panel: Value Cost Effectiveness: Implications of the Changing Landscape in Reimbursement and Regulations    


  • Chris Coburn, Vice PresidentInnovation, Partners HealthCare
  • Geoff MacKay,President & CEO, Organogenesis
  • Christina Severin, President & CEO, Beth Israel Deaconess Care Organization


12:00 pm – 12:30pm        Remarks by FDA Commissioner Margaret Hamburg 

Introduction by Senator Elizabeth Warren

12:30 pm - 12:45 pm        Lunch is Served

12:45 pm – 1:30 pm         Closing Keynote: Flemming Ornskov, CEO of Shire

1:30 pm – 2:00 pm           Dessert Buffet in the Ballroom Foyer               




Share MassBio